What is Ezetimibe Used For?
Ezetimibe is a cholesterol absorption inhibitor used to lower LDL cholesterol (LDL-C) in patients with hyperlipidemia, either as monotherapy when statins cannot be used, or more commonly as add-on therapy to statins when LDL-C goals are not achieved with statin therapy alone. 1, 2
Primary FDA-Approved Indications
Ezetimibe is FDA-approved for the following specific uses 1, 2:
In Adults:
- Primary hyperlipidemia (including heterozygous familial hypercholesterolemia): To reduce total cholesterol, LDL-C, ApoB, and non-HDL-C, either alone or combined with a statin
- Mixed hyperlipidemia: Combined with fenofibrate to lower LDL-C
- Homozygous familial hypercholesterolemia (HoFH): Combined with atorvastatin or simvastatin
- Homozygous sitosterolemia: To reduce sitosterol and campesterol levels
In Children:
- Ages ≥10 years: With a statin for heterozygous familial hypercholesterolemia (HeFH) or homozygous familial hypercholesterolemia (HoFH)
- Ages ≥9 years: For homozygous familial sitosterolemia
Mechanism of Action
Ezetimibe works by inhibiting the NPC1L1 protein at the brush border of the small intestine, blocking absorption of both dietary cholesterol and cholesterol from bile 1, 3. This mechanism is complementary to statins, which reduce cholesterol synthesis in the liver.
Clinical Efficacy
LDL-C Reduction
- Monotherapy: Reduces LDL-C by approximately 18-20% 1, 3
- Combination with statin: Provides an additional 21-25% incremental LDL-C reduction beyond statin alone 1, 4
Cardiovascular Outcomes
The most compelling evidence for ezetimibe's cardiovascular benefit comes from two major trials 1:
IMPROVE-IT trial: In patients with recent acute coronary syndrome on moderate-intensity statin therapy, adding ezetimibe resulted in:
- Further LDL-C lowering
- Reduced composite endpoint of CV death, nonfatal MI, unstable angina requiring hospitalization, coronary revascularization, or nonfatal stroke
- Median follow-up of 6 years
SHARP trial: In patients with chronic kidney disease, simvastatin plus ezetimibe reduced major atherosclerotic cardiovascular disease events compared to placebo over 4.9 years median follow-up.
Current Guideline Recommendations
When to Add Ezetimibe
According to the 2022 ACC Expert Consensus 1:
For patients with ASCVD or severe hypercholesterolemia:
- Add ezetimibe when LDL-C remains elevated despite maximally tolerated statin therapy
- Particularly reasonable when LDL-C ≥100 mg/dL on maximal statin therapy 5
- First-line add-on therapy before considering PCSK9 inhibitors due to better tolerability, lower cost, and generic availability 6
The 2020 ESC guidelines 6 recommend:
- Adding ezetimibe to statin therapy when LDL-C goals are not achieved with maximum tolerated statin dose
- This approach provides better lipid control with comparable or better tolerability than up-titrating statin doses
Special Populations
Elderly patients (≥75 years): The EWTOPIA 75 study demonstrated that ezetimibe monotherapy reduces ASCVD events in primary prevention for patients ≥75 years old, likely due to increased cholesterol absorption efficiency with age 7
Statin-intolerant patients: Ezetimibe can be combined with bempedoic acid for significant LDL-C reduction when statins cannot be tolerated 8
Dosing and Administration
- Standard dose: 10 mg orally once daily, with or without food 1, 2
- With bile acid sequestrants: Take ezetimibe at least 2 hours before or 4 hours after the bile acid sequestrant 2
- Generally well tolerated with a favorable safety profile 1, 8
Safety Considerations
Contraindications
Warnings
- Monitor liver enzymes when used with statins 1, 2
- Risk of myopathy/rhabdomyolysis increases when combined with statins or fibrates 1, 2
- Not recommended in moderate to severe hepatic impairment 1
- Avoid in pregnancy; unknown safety in breastfeeding 2
Clinical Advantages
Ezetimibe offers several practical benefits 6, 8:
- Better tolerability than statin dose escalation with fewer adverse effects
- Improved adherence due to simplified regimen and fewer side effects
- Generic availability making it cost-effective
- Synergistic effect when combined with statins
- Fixed-dose combinations available with various statins